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MOST people would agree that studies with transplanted tumours have given
information concerning the autonomy of malignant tumours and concerning
their histogenesis. However, there is a tendency to regard such studie8 as some-
what old-fashioned and this field of study more or less closed. In this paper it
is hoped to show that there is still valuable information to be gathered of
significance for generalbiology as well as oncology.
General biology and tumour transplantation.
The genetical laws governing the transplantation of normal and malignant
tissues are now generally accepted. In both cases a complex of dominant genes
is concerned which Snell (1948) has called histocompatibility genes. There have
always been two schools ofthought conceming the nature ofthese genes, gne that
the genes determine iso-antigenic differences, the other that they deterinine
" individual differentials "-substances with somewhat mysterious and ill-defined
properties.
It is not easy to study these questions with normal tissues for technical
reasons, one ofwhich is that the number offactors isalwayshigh. With tumours
the number varies, but may be low, and in addition tumours stimulate a better
antibody response.
Iso-immune reactions are most easily studied in the erythrocytes, and it so
happens that certain important iso-antigens in Strong's A strain of mice are
shared by the erythrocytes and fixed tissues. The same is true of certain other
strains, but the A strain is the easiest to work with. Four tumours from this
strain have been studied genetically and serologically.
The first two were studied in England; in both it appeared that two histo-
compatibility genes were concerned, one of which was identical with a gene for
an antigen known as antigen II. By serological means it was shown that the
tumours contained anotherantigen in addition to 11. Occasionally iso-antibodies
were formed against it, but too irregularly 4nd at too low a titre to be of value
forgenetical work (Gorer, 1937, 1938, 1942).
Those studied in America were both found to give single gene ratios in back-
crosses. Theimportance ofantigen11 wasagaindemonstrated(Table1). Further-
more, in conjunction with Snell and Lyman (Gorer, Snell and Lyman, 1948) it
was possible to show close linkage between antigen 11 and the locus for
" fused
"
(a tail anomaly). Full information is to be published elsewhere, but it can be
seen from Table 11 that thelinkage is close. We obtained very similar data with
a dba tumour. The antigen concemed is closely related to II chemically, and
for this reason we think it likely that the two genes are alleles which we have
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1 3pi- 38 Antigen 11 present I.
Antigen 11 absent
Totals .
TABLE II.-Te8t for Linkage
29 40 69
with Antigen II and Fused.
















NOTE.-The numbers in parentheses are the approximate number of mice expected in each class
if the genes for antigenic constitution and
" fused
" or normal tails were on different chromosomes.
TABLE III.-The Antigenic Similarity Between A -and dba Red Cells.
Serum anti-15091a diluted I in- Tested on
cells of- 2 4 . 8 . 16. 32. 64. 128. 256.
A . +±
db.-2 .
a.c. ++± + + a.c. a.c.
Serum tested on A cells after absorption (at 1/8).
Dilution of serum.
r--- 1.





NOTE.-15091a is an A strain tumour. The sera were produced by inoculation of C57 blacks.
The similarity is not shown to the same degree by all sera.
provisionally called H2 and H2d (Table 111). Closely related antigens occur in
strains CBA and-CM, so perhaps,there is a long series of alleles at this locus.
We are not certain how many cross-overs there were. Animals carrying the
gene for fused may have norm'al tails, and there are other difficulties associated
with tumour transplantation that will be discussed later on. In backerosses
involving 257 animals the recombinations were between 0 and 5 per cent.
Previous to these studies Strong (1929) had used tumour transplantation to
show sex linkage of a histocompatibility gene, and Bittner (1933) found loose
linkage with
" dilution." The location ofH2 was first foundby Snell andLyman
using tumour.inoculation without serological testing, and I hope I ambetraying
no confidences by saying that they have other instances oflinkage as well. It
will be seen that tumour inoculation is -a most useful weapon in mapping chromo-
somes. Naturall it is best to use serological tests as well. but these m be y ay105 STUDIES WITH TRANSPLANTED TUMOURS
difficult. We may be certain that not all the pertinent antigens are shared by
the transplanted tissues and the red cells-a fact that greatly increases technical
difficulties.
Before discussing some of the pitfalls that may occur in detecting cross-overs
by tumour transplantation it may not be amiss to call attention to another
problem of interest to pu-re genetics, namely, polymorphism. In his discussion
Ford (194-5) alludes to the question of serological differences in man. f believe
that all mammals (and perhaps many other forms) are polymorphic for histo-
compatibility genes, ofwhich the blood groups,etc., are special instances. I have
examined a few wild mice alltrapped in the same premises. Without going into
details it may be said that they were not serologically uniform. Tumour trans-
plantation indicates that this polymorphism may be maintained by a high
mutation rate. Pure strains unless kept on a very small scale automatically
crystallize into various sub-strains. It was shown by Bittner (1935) that a dba
tumour would not take in allsub-strains, and this has been found to be a common
finding,having been seen with various tumours arising in strains C57 black(Law,
1942 ; Gorer, unpublished) and CM (Gross, 1947). The phenomenon could
probably be found in all strains if sufficiently delicate methods are used. The
reason for this is obscure. We have as yet no'evidence thatliability to disease is
influencedbvantigemcconstitution, orindeedverylittleknowledgeoftheantigens'
functions in the cell. Perhaps the polymorphism is connected with the risk of
iso-i'mmunization during pregnancy; this must be great where foetal absorption
is common. If a species were completely uniform the risk would vanish, but it
is unlikely that any species would be completely so over the whole of its rangle.
On the other hand, if it were sufficiently polymorphic, the danger may be mini-
mized. If a male has a rare antigen he wouldprobably beheterozygous, andonly
halfthe litter would perish ifiso-immunization took place. Further, inmatings
with different males, a female would be unlikely to receive successive doses of
the same antigen. Lastly, it is possible that if a mixture of a large -number of
antigens is received, dangerous titres of antibodies are not formed against any
one of them. Antigen II does not appear to be very mutable, but here mice
also seem very'polymorphic. Eight pure strains have been examined; all are
somewhat different. As we have seen, there may be a large series ofalleles here.
The most powerful in this group (H2--) is almost recessive to the allele in the C57
blacks, which is apparently non-antigenic. It is as though
" 0
" in man was
almost dominant over A or B-an interesting feature in view of Fisher's theory
of dominance.
Transplantation and oncology.
To return more closely to the cancer problem, we may ask: If an A strain
tumour gives a single gene ratio in crosses with C57 blacks, does this mean that
they contain only one factor antigenic for the latter strain ? The answer is in
the negative. Both the tumours tested in Bar Harbor gave such a ratio, but it
was shown conclusively that they both contained at least two antigens. This is
easily explained immunologically. Antigens differ greatly in potency. Thus in
man iso-immunization happens frequently against the classical Rhesus factor
(Ro or D), but very seldom against antigen M. This doubtless explains the fact
illustrated in Table I that mice with antigen 11 were resistant to tumour inocula-
tion. If we were to breed from the 3 resistant young by crossing with a resistant106 P. A. GORER
strain, we would get about 50 per cent susceptible progeny (MacDowell and
Richter, 1932).
Errors of the above t-vpe are counterbalanced by precisely the opposite effect.
Some tumours may grow and kill the host in spite of iso-antigenic differences.
There is considerable indirect evidence of this, but recently it has been possible
to show that an animal succumbing to a tumour derived from any other strain
may form high titresofantibodies (Gorer, 1947). In many experiments these two
sources of error usually seem to cancel themselves out, as the correspondence
with Mendelian expectation is generally satisfactory. They may give rise to
serious error in attempting to identify individuals as cross-overs or non-cross-
overs, etc.
So far as the cancer problem itself is concerned, the latter of these two,
anomalies is by far the more interesting, since it helps to throw somelight on the
difference between normal and neoplastic cells and upon the effect of a neoplasm
upon the individual bearing it.
It is now well known that tumours may
" mutate." In general it may be
said that tumours that have been transplanted a number of times appear to
possess fewer antigens than they .id at first. When first tested a tumour may
appear to have upwards of 7 factors; later on, only one or two. Differences of
this order cannot be accounted for by errors of the type just mentioned. There
must be some realantigenic alteration. This might be due to mutations ofdomi-
nants to recessive alleles. This is extremely improbable ; one would have to
have 6 or 7 homozygous mutations. A quantitative serological study of certain
A strain tumours has given evidence that some antigens are greatly increased
in amount. What may happen is that one or more antigens crowd the others
out. Iffor the sake ofargument we assume that antigen 11 occupies 10 per cent
of the surface of a normal cell, in a malignant one it may occupy 90 per cent.
These experiments have the disadvantage that we have no really satisfactory
normal control.. For example, we can show that the cells of a myeloblastic
leukaemia contain increased amounts of antigen 11, but we cannot get enough
normal myeloblasts for comparison. There is evidence that analogous antigenic
alterations may occur in human tumours. Zacho (1932) showed that t'he antigens
M and N arepresent in increased amount inmalignant tissues. With tumours of
the alimentary canal one should be able to obtain sufficient normal mucosa for
comparison. It is hoped during the coming year to study various antigens in
this way.
We have already seen that the ability of a tumour to grow in an alien strain
does not indicate complete loss of strain specific antigens. How, then, does it
maintain itself ? There is probably no simple answer to this question. Appa-
rently the cells can maintain themselves in the presence of high titres of anti-
bodies. Bacteria do the same thing in fatal cases of typhoid, streptococcal
septicaemia, etc., although we do not know how.
Inaddition, there would appear to be somedepressant effect upon the reticulo-
endothelial system exerted to a lesser or greater degree by allmalignant tumours
Victor and Potter (1938) have shown that the metabolism of lymph nodes is..
depressed by inoculated leucotic cells, even though they have not yet become
demonstrably invaded by them. Blumenthal (1942) has shown that animals
with spontaneous mammary tumours are more susceptible than controls to
implants of tumours from alien strains. Lastly, we have some evidence thatSTUDIES WITH TRANSPLANTED TUMOURS 107
animals with transplanted (Browning, 1947) and induced tumours (Gorer, un-
published) are more susceptible to bacterial infection than are normal animals.
One needs a great deal more information on this point, using pregnant animals,
and animals with grafts of embryonic tissues as controls. This may turn out to
be an important property of malignant growths. At present the bulk of expert
opinion is against invoking any direct toxic effect of tumours to account for the
illness one observes in human cancer. This is quite logical. There are numerous
reasons why a cancer patient should be ill. However, work with transplanted
tumours suggests that the subject cannot be considered closed.
SUMMARY.
1. Tumour transplantation was used to show the antigenic basis of trans-
plantation immunity in general.
2. One ofthe pertinent histocompatibility genes has been shown to be closely
linked to the gene for a tail anomaly in mice.
3. It is believed that all mammals (and perhaps many other forms) are highly
polymorphic for histocompatibility genes. There is evidence that some of these
genes have a high mutation rate in mice. The possible significance of this is
discussed in the text.
4. Serological studies show that tumours may kill an animal in spite of anti-
genic differences. Some antigens are weak, and rarely elicit an effective defensive
reaction. Genetic studies on transplantation are therefore not a completely
accurate indication of antigenic structure.
5. Tumours undergo some antigenic simplification during transplantation.
Probably one or two antigens increase in amount and crowd out the others.
6. Malignant tumours appear to exert a depressive action on the defences of
the host.
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